Effectiveness and safety of serplulimab plus platinum-based chemotherapy in first-line treatment of extensive-stage small cell lung cancer liver metastases: a retrospective cohort study.

ABSTRACT:

Background

The role of immunotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC) liver metastases remains controversial. This study aimed to evaluate the effectiveness and safety of serplulimab combined with platinum-based chemotherapy as a first-line treatment for these patients.

Methods

This retrospective cohort study reviewed patients with ES-SCLC liver metastases who received serplulimab plus platinum-based chemotherapy as a first-line treatment. Outcomes included objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety. The associations between prognosis and the depth of remission of primary lung lesions and liver metastases were analyzed.

Results

Among the 30 ES-SCLC patie

SUBMITTER: Chen Y 

PROVIDER: S-EPMC12507603 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature